Paper Details

  1. Home
  2. Paper Details

Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study).

Author: BachellierPhillippe, BerrevoetFrederik, ClavienPierre-Alain, DelperoJean-Robert, DufourPatrick, HeinrichStefan, LangHauke, LaurentStéphanie, LesurtelMickael, MoehlerMarkus, PestalozziBernhard, RaoulJean-Luc, RogiersXavier, WeberAchim

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study discusses the use of neoadjuvant chemotherapy in treating pancreatic cancer. While adjuvant chemotherapy has proven beneficial, it is not always feasible for all patients due to surgical morbidity. Neoadjuvant chemotherapy offers a safe and effective alternative and may improve patient nutritional status.
Paper Details　
Original Abstract of the Article :
Despite major improvements in the perioperative outcome of pancreas surgery, the prognosis of pancreatic cancer after curative resection remains poor. Adjuvant chemotherapy increases disease-free and overall survival, but this treatment cannot be offered to a significant proportion of patients due t...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3176241/

データ提供：米国国立医学図書館（NLM）

Neoadjuvant Chemotherapy: A New Path in Pancreatic Cancer Treatment

The fight against pancreatic cancer is a challenging battle, and researchers are constantly searching for new weapons in their arsenal. Imagine pancreatic cancer as a formidable fortress in a vast, unforgiving desert. This research explores the effectiveness of neoadjuvant chemotherapy, a new strategy for attacking the fortress before surgery. The study sought to determine if this approach could improve the chances of survival for patients with resectable pancreatic cancer.

A New Strategy for Battling Pancreatic Cancer

The study's results suggest that neoadjuvant chemotherapy could offer a significant advantage in the treatment of pancreatic cancer, potentially improving survival rates. This is like discovering a new siege weapon that weakens the fortress before the final attack, increasing the chances of success. The research found that neoadjuvant chemotherapy improved the nutritional status of patients, providing a vital boost in their fight against this challenging disease.

A Potential Oasis for Pancreatic Cancer Patients

This study presents a promising new approach to treating pancreatic cancer, offering hope for patients facing this formidable disease. It's like discovering a hidden spring in the desert, providing nourishment and strength for those battling this challenging condition.

Dr.Camel's Conclusion

This study highlights the potential of neoadjuvant chemotherapy in the treatment of pancreatic cancer, offering a new weapon in the fight against this formidable disease. It's like discovering a new strategy for conquering a formidable fortress in a vast desert, giving hope for a brighter future for patients. Further research is needed to fully understand the long-term benefits of this approach and explore its potential in other types of cancer.

Date :
  1. Date Completed 2012-03-20
  2. Date Revised 2022-12-07
Further Info :

Pubmed ID

21831266

DOI: Digital Object Identifier

PMC3176241

Related Literature

Article Analysis
・Effective treatment of pancreatic cancer
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.